Edity Therapeutics Enters into a Strategic Co-Development Partnership with Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors

REHOVOT, Israel – WEBWIRE – Thursday, April 3, 2025 Edity Therapeutics Limited and Aurigene Oncology Limited (AOL), a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited, a clinical-stage biotechnology company, announced